Author

Pamela S. VanderVere-Carozza

Indiana University Indianapolis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:CUT&Tag· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

John J. TurchiiD· 2 shared Matthew R. JordaniD· 2 shared Athena K. Petrides· 1 shared Diana AinembabaziiD· 1 shared Hilary D. Hinshaw· 1 shared Joy Garrett· 1 shared Jun WaniD· 1 shared Karen E. PollokiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

John J. TurchiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistryJournal of Biological ChemistryPeer-reviewedMay 17, 2025

Biochemical Impact of p300-Mediated Acetylation of Replication Protein A: Implications for DNA Metabolic Pathway Choice

Onyekachi E. Ononye, Sneha Surendran, Tripthi Battapadi…·Lata Balakrishnan

This study shows that p300-mediated acetylation of RPA enhances its ssDNA binding affinity, particularly during G1/S phase and UV damage, influencing DNA metabolic pathway choice.

2 citations

proteomicsexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 9, 2025

Chemical inhibition of RPA gap protection sensitizes BRCA1-deficient cancers to PARP inhibition

Pamela S. VanderVere-Carozza, Matthew R. Jordan, Joy Garrett…·John J. Turchi

This study shows that inhibiting RPA gap protection enhances PARP inhibitor efficacy in BRCA1-deficient cancers by increasing genomic instability and reducing tumor growth.

DOI 10.1101/2025.04.09.647957

humanCUT&Tag

𝕏 PostBluesky